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Summary
 
The extracellular signal-regulated kinase (ERK), the c-Jun NH
 
2
 
-terminal kinase (JNK), and
p38 MAP kinase pathways are triggered upon ligation of the antigen-specific T cell receptor
(TCR). During the development of T cells in the thymus, the ERK pathway is required for
differentiation of CD4
 
2
 
CD8
 
2
 
 into CD4
 
1
 
CD8
 
1
 
 double positive (DP) thymocytes, positive se-
lection of DP cells, and their maturation into CD4
 
1
 
 cells. However, the ERK pathway is not
required for negative selection. Here, we show that JNK is activated in DP thymocytes in vivo
in response to signals that initiate negative selection. The activation of JNK in these cells ap-
pears to be mediated by the MAP kinase kinase MKK7 since high levels of MKK7 and low lev-
els of Sek-1/MKK4 gene expression were detected in thymocytes. Using dominant negative
JNK transgenic mice, we show that inhibition of the JNK pathway reduces the in vivo deletion
of DP thymocytes. In addition, the increased resistance of DP thymocytes to cell death in these
mice produces an accelerated reconstitution of normal thymic populations upon in vivo DP
elimination. Together, these data indicate that the JNK pathway contributes to the deletion of
DP thymocytes by apoptosis in response to TCR-derived and other thymic environment–
mediated signals.
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T
 
he development of T cells occurs in the thymus where
bone marrow precursor cells differentiate through
multiple developmental stages involving maturation, prolif-
eration, selection, and death. Early precursor cells that are
initially CD4
 
2
 
CD8
 
2
 
 double negative (DN)
 
1
 
 differentiate
into CD4
 
1
 
CD8
 
1
 
 double positive (DP) cells. This process is
controlled by a series of phenotypic changes, with the ex-
pression of the pre-TCR (at the DN stage) and the TCR
(at the DP stage) being the most critical. DP thymocytes
differentiate into mature single positive (SP) CD4
 
1
 
 and
CD8
 
1
 
 thymocytes that are ready to leave the thymus and
migrate to the periphery. However, before completing
their maturation, DP and immature CD4
 
1
 
 and CD8
 
1
 
 thymo-
cytes undergo positive and negative selection. Recognition
of peptides by thymocytes in the context of the self-MHC
leads to their rescue from apoptosis and their migration
to the periphery (positive selection), while recognition of
self-peptides induces death of the autoreactive T cells in
the thymus by apoptosis (negative selection) (1–3). It re-
mains unclear whether the signals mediated by the TCR
during the selection of thymocytes and the activation of
peripheral T cells are quantitatively or qualitatively differ-
ent. Various models have been proposed to explain how
recognition of each peptide-MHC complex results in a dif-
ferent final outcome. Quantitative models propose that the
strength of the TCR signal determines whether a peptide
causes positive or negative selection depending on the af-
finity of the TCR–MHC-peptide complexes. High inten-
sity signals cause cell death, whereas low intensity signals
rescue thymocytes from apoptosis. On the other hand,
 
1
 
Abbreviations used in this paper:
 
 Cyt c, cytochrome c; DN, double nega-
tive; DP, double positive; ERK, extracellular signal-regulated kinase;
GST, glutathione S-transferase; hGH, human growth hormone; JNK, c-Jun
NH
 
2
 
-terminal kinase; SP, single positive.
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qualitative models consider that different signaling path-
ways control positive and negative selection of the imma-
ture thymocytes.
The MAP kinases play a key role in a variety of cellular
responses. Several parallel MAP kinase signal transduction
pathways have been defined in mammalian cells (4, 5). The
extracellular signal-regulated kinase (ERK) family has been
associated with the proliferation and differentiation of a
number of different cell types, while the c-Jun NH
 
2
 
-termi-
nal kinase (JNK) and the p38 families have been associated
with apoptotic death in several systems (4, 5). During acti-
vation of T lymphocytes, these pathways are triggered
upon ligation of the antigen-specific TCR, although JNK
but not ERK activation needs a second signal provided by
costimulatory molecules (6). During the development of T
cells in the thymus, the Ras/Raf–ERK pathway is required
for differentiation of immature thymocytes from the DN to
the DP stage (7), positive selection of T cells (8–12), and T
cell lineage commitment (13). However, negative selection
of autoreactive T cells does not involve the ERK signaling
pathway (8). In contrast to JNK, p38 MAP kinase is consti-
tutively activated in DN and DP thymocytes, probably
maintained by stimuli derived from the thymic environ-
ment (14). The role of the p38 MAP kinase pathway in
positive and negative selection remains to be addressed.
The JNK MAP kinase group consists of three different
members (JNK1, JNK2, and JNK3) and at least 10 different
isoforms which result from alternative splicing of these
three genes (15). JNK1 and JNK2 are widely expressed in sev-
eral tissues, whereas JNK3 is more selectively expressed in
brain, testis, and heart. The specific contribution of these JNK
isoforms to T cell development remains unknown. In cor-
relation with previous studies indicating a role of the JNK
signaling pathway in cell death (5), we have shown recently
that disruption of the JNK3 gene results in the abrogation
of neuronal apoptosis in response to exocitotoxic stress
(16). JNK family members are regulated and activated by
MAPK kinases. Two MAPK kinases, MKK4 and MKK7,
have been found to be the primary activators of JNK (17–20).
Here we have examined the regulation and function of
the JNK pathway in the deletion of DP thymocytes in re-
sponse to signals that initiate negative selection. TCR
ligands activate JNK in vivo, and this process is associated
with cell death and DP thymocyte deletion. Using trans-
genic mice overexpressing a dominant negative mutant of
JNK1 (dnJNK1), we demonstrate that inhibition of the JNK
signaling pathway results in increased resistance of DP thy-
mocytes to cell death in response to TCR- and thymic mi-
croenvironment–mediated signals. Thus, this study indicates
that JNK is activated and contributes to the negative selec-
tion of DP thymocytes and supports the qualitative signal-
ing model to distinguish positive and negative selection.
 
Materials and Methods
 
Generation of dnJNK1 Transgenic Mice.
 
A cDNA encoding the
dominant negative form of JNK1, where Thr
 
183
 
 was replaced by
Ala and Tyr
 
185
 
 was replaced by Phe (21), was subcloned down-
stream of the distal promoter of 
 
lck
 
 (22). A 2-kb fragment from
the human growth hormone (hGH) was used to provide the
polyadenylation and intron sequences (23). The DNA fragment
containing the distal 
 
lck
 
 promoter, the dnJNK1 cDNA, and the
hGH region was injected in (C57BL/6 
 
3
 
 C3H)F
 
2
 
 eggs to gener-
ate the dnJNK1 transgenic mice, as previously described (24).
Three expression-positive founder lines were established and
backcrossed onto B10.BR (The Jackson Laboratory, Bar Harbor,
ME) to obtain the progeny for these studies.
 
Cell Preparation and Staining.
 
CD4
 
1
 
 T cell populations were
isolated from spleen and lymph nodes from wild-type and trans-
genic mice by negative selection as previously described (25, 26).
The DP thymocytes used for the in vivo activation of JNK1 were
obtained by staining with a FITC-conjugated anti-CD8 mAb
(PharMingen, San Diego, CA) and a PE-conjugated anti-CD4
mAb (PharMingen) and cell sorting using a flow cytometer (EP-
ICS; The Coulter Corp., Miami, FL).
Expression of CD4 and CD8 was analyzed by cell surface
staining using a FITC-conjugated anti-CD8 mAb and Red
 
613
 
-
conjugated anti-CD4 mAb (GIBCO BRL, Gaithersburg, MD).
A biotinylated anti-V
 
b
 
3 mAb (PharMingen) was used in combi-
nation with PE-conjugated streptavidin to determine the expres-
sion of V
 
b
 
3 in the different populations by three color staining.
 
Reverse Transcription-PCR.
 
Cytoplasmic RNA was obtained
from different tissues, as previously described (27). First strand
cDNA was synthesized from 5 
 
m
 
g of RNA by using reverse
transcriptase (GIBCO BRL) for 1 h at 37
 
8
 
C (50 
 
m
 
l final vol-
ume). 1/5 of the cDNA reaction was used for the PCR reaction
to amplify the dnJNK1 transcript or the endogenous JNK1; 1/25
of the cDNA was used for detection transcripts of the 
 
g
 
-actin and
hypoxanthine-guanine phosphoribosyl transferase (HPRT) house-
keeping genes. After 35 cycles, 15 
 
m
 
l of the reaction (50 
 
m
 
l) was ana-
lyzed by gel electrophoresis and detected by ethidium bromide stain-
ing. Two specific primers for mouse JNK1 were used to detect
endogenous JNK1, a 5
 
9
 
 primer (5
 
9
 
 GTGTGCAGCTTATGATGC-
TATTCTTGAA 3
 
9
 
) and a 3
 
9
 
 primer (5
 
9
 
 TTTGGATAACAAAT-
CTCTTGCC 3
 
9
 
). A primer located in human JNK1 (5
 
9
 
 primer, 5
 
9
 
GCCCTCTCCTTTAGCACAG 3
 
9
 
) and a second primer corre-
sponding to the hGH region used to provide the polyadenylation
and intron sequences (23) for the transgene (3
 
9
 
 primer, 5
 
9
 
 CAGAA-
CCCCCAGACCTCCCTC 3
 
9
 
) were used to analyze the expres-
sion of the dnJNK1 transgene.
 
JNK1 Activity.
 
JNK activity in cell lysates was performed by
immunoprecipitation of JNK1 kinase and incubation with the
substrate glutathione S-transferase (GST)–c-Jun immobilized on
GSH-agarose beads, as previously described (21, 26, 28). After 12 h
at 4
 
8
 
C, the beads were washed extensively in lysis buffer followed
by kinase assay buffer (25 mM Hepes, pH 7.4, 25 mM 
 
b
 
-glycero-
phosphate, 25 mM MgCl
 
2
 
, 0.1 mM sodium orthovanadate, 0.5 mM
dithiothreitol) and the activity of the bound JNK was detected by
the addition of [
 
g
 
-
 
32
 
P]ATP for 30 min at 30
 
8
 
C. The reaction
products were resolved by SDS-PAGE and the incorporation of
[
 
32
 
P]phosphate was quantitated by PhosphorImager analysis (Mo-
lecular Dynamics, Sunnyvale, CA).
 
AP-1 Transcriptional Activity.
 
AP-1 transcriptional activity was
determined by analysis of the luciferase activity in the cell extracts
from AP-1–luciferase reporter transgenic mice (25) using the
Luciferase Assay Kit (Promega Corp., Madison, WI).
 
Reagents.
 
PMA (Sigma Chemical Co., St. Louis, MO), iono-
mycin (Sigma Chemical Co.), Con A (Boehringer Mannheim,
Mannheim, Germany), anti-CD3 mAb (145-2C11), synthetic
moth cytochrome c (Cyt c) peptide (Peptide Synthesis Facility,
Yale University, New Haven, CT), and Staphylococcus entero- 
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toxin B (Sigma Chemical Co.) were obtained from the suppliers
indicated; GST–c-Jun (residues 1–79) was described previously (21).
 
Western Blot Analysis.
 
MKK4 and JNK protein levels were
assayed by immunoblot analysis using anti–human MKK4 and
anti–human JNK mAb (PharMingen). Immune complexes were
detected by enhanced chemiluminescence as instructed by the
manufacturer (Amersham International, Little Chalfont, UK).
 
RNA Extraction and Northern Assay.
 
Total RNA from brain
or thymus was extracted using the Ultraspec RNA isolation system
(Biotex Laboratories, Inc., Houston, TX) as recommended by the
manufacturer. Total RNA (8 
 
m
 
g) was analyzed by Northern blot as
previously described (29). A 500-bp EcoRV MKK4 cDNA frag-
ment and a 1.3-kb EcoRI-XbaI MKK7 cDNA fragment were
used as specific probes labeled by random primer using the Ran-
dom Primer Kit (Stratagene Inc., La Jolla, CA) using [
 
a
 
-
 
32
 
P]dCTP.
 
Results
 
Regulation of JNK Activity in CD4
 
1
 
CD8
 
1
 
 Thymocytes.
 
The ERK MAP kinase pathway is required for positive se-
lection, but not for negative selection in the thymus (8–
11). JNK, another member of the MAP kinase family, has
been reported to be activated in total thymocytes in re-
sponse to TCR-independent stimulus (6). However, the
regulation of JNK activity by TCR-mediated signals in im-
mature CD4
 
1
 
CD8
 
1
 
 (DP) has not yet been examined.
Since activation of JNK has also been associated with cell
death in other cell types (4, 5), we examined whether the
JNK pathway could also be involved in the deletion of DP
cells during negative selection in the thymus. We examined
the regulation of JNK in this population upon ligation of
the TCR. The cross-linking of the TCR by an immobi-
lized anti-CD3 mAb did not upregulate JNK activity in
isolated DP thymocytes (Fig. 1 
 
A
 
). Previous studies indi-
cate that the activation of JNK in the Jurkat T cell line ap-
pears to require signals mediated by both the TCR and co-
stimulatory molecules such as the CD28 (6). Therefore, we
also examined the regulation of JNK in the presence of co-
stimulatory signals. However, stimulation with anti-CD3
mAb in combination with anti-CD28 mAb did not cause a
significant increase of JNK activity in DP thymocytes (Fig.
1 
 
A
 
). These results suggested that TCR-mediated JNK ac-
tivation may require costimulatory signals other than those
mediated by CD28 in DP thymocytes.
To examine the regulation of JNK in DP thymocytes
upon ligation of the TCR in the context of other thymic
environmental signals in vivo, we examined JNK activity
induced by injection with anti-CD3 mAb. JNK activity was
significantly increased in DP thymocytes isolated from mice
injected with anti-CD3 mAb (Fig. 1 
 
B
 
) before the deletion
of these cells. These results indicate that activation of the
JNK pathway can be triggered in DP thymocytes by TCR
ligation in combination with costimulatory signals other
than CD28 that are provided by the thymic environment.
The additional thymic environmental signals that are re-
quired for TCR-mediated JNK activation could be pro-
vided by soluble factors or cell surface molecules. To ad-
dress this question further, we examined the regulation of
JNK activity in DP thymocytes upon stimulation with Con
A in vitro. It is known that Con A activates mature T cells
by ligation of the TCR, but also activates other, additional
molecules (30). Purified DP thymocytes were stimulated
with Con A alone. Interestingly, in contrast to the combi-
nation of anti-CD3 and anti-CD28 mAbs, Con A signifi-
cantly upregulated JNK activity in DP thymocytes (Fig. 1
 
C
 
). These results supported the hypothesis that activation
of JNK by TCR ligation requires signals mediated by co-
Figure 1. Regulation of JNK activation in DP thymocytes. (A) JNK activity in stimulated DP thymocytes in vitro. DP thymocytes were obtained by
staining of total thymocytes with an anti-CD4 and anti-CD8 mAb and cell sorting (FACSÒ). Purified DP thymocytes (5 3 105 cells) were incubated in
the presence of medium (2), immobilized anti-CD3 mAb (10 mg/ml) (anti-CD3), or immobilized anti-CD3 (10 mg/ml) plus anti-CD28 (10 mg/ml)
mAbs (anti-CD3/CD28) for 3 h. JNK1 was immunopurified from DP extracts and assayed for kinase activity in vitro using the GST-cJun as substrate. The
radioactivity incorporated into GST–c-Jun was quantitated after SDS-PAGE by PhosphorImager analysis. (B) Activation of JNK1 upon in vivo anti-CD3
mAb injection. Wild-type mice were injected with PBS (2) or anti-CD3 mAb (2C11, 50 mg/200 ml PBS) for 6 or 12 h. Total thymocytes were stained for
CD4 and CD8, and DP thymocytes (4 3 105 cells) were isolated by cell sorting. JNK1 was immunopurified from DP extracts and assayed for kinase ac-
tivity, as described in A. (C) Activation of JNK1 upon Con A stimulation in vitro. DP thymocytes (5 3 105 cells) were obtained as described in A and
treated with medium alone (2) or Con A (2.5 mg/ml) for 2 or 4 h. JNK1 activity was determined as described in A.1820 JNK Signaling Pathway in Thymic Development
stimulatory molecules different from CD28 molecule in
DP thymocytes.
It is well accepted that negative selection of DP thy-
mocytes also requires costimulation in addition to TCR-
mediated signals (31–33). However, the nature of the co-
stimulatory signal provided by the thymic environment and
the role of CD28 as a costimulator in the thymus remain
unclear. In correlation with previous studies (34), we found
that in vitro treatment of total thymocytes with immobi-
lized anti-CD3 and anti-CD28 mAbs did not cause signifi-
cant elimination of the DP cells, but resulted in reduced
expression of CD4 and CD8 on the surface of DP thy-
mocytes (Fig. 2 A). The downmodulation of CD4 and
CD8 molecules has been associated with the induction of
apoptosis in thymocytes (35). No substantial reduction of
the number of total thymocytes was observed upon treat-
ment with anti-CD3/anti-CD28 mAbs compared with un-
treated thymocytes (data not shown). The deletion of the
DP population was not increased even after extended peri-
ods of activation (data not shown). In contrast, the in vivo
administration of anti-CD3 mAb or specific antigen causes
deletion of the majority of the DP thymocytes by inducing
apoptotic cell death through a mechanism that mimics neg-
ative selection (36–40). In correlation with these studies, a
pronounced deletion of the DP thymocyte population was
detected 48 h after treatment with anti-CD3 mAb in vivo
(Fig. 2 A). These results support the hypothesis that the
elimination of immature DP thymocytes requires signals
additional to the TCR provided by the thymic environ-
ment. Unlike anti-CD3 plus anti-CD28, stimulation with
Con A in vitro also caused a rapid and dramatic thymocyte
cell death. A massive loss of the number of DP thymocytes
was observed (data not shown), and the percentage of DP
cells in the live population was also reduced (Fig. 2 B)
upon Con A treatment in vitro. Thus, the signal require-
ment for deletion of DP thymocytes correlates with the
signals needed for TCR-mediated JNK activation.
JNK activity is regulated by phosphorylation by an up-
stream MAPK kinase. Two different MAPK kinases have
been identified that phosphorylate and activate JNK,
MKK4/Sek1 and MKK7 (17–20). The specific contribu-
tion of these two protein kinases to the control of JNK ac-
tivity in different cell types remains unclear. In addition,
the relative expression of the two JNK activators in the
murine thymus has not yet been addressed. Thus, we ex-
amined the expression of both the MKK4 and MKK7
genes in total thymocytes. High levels of MKK7 mRNA
were detected in the thymus (Fig. 3 A), similar to those de-
tected in the brain. Interestingly, although MKK4 was ex-
pressed in the brain as previously described (17, 18, 20), no
significant level of MKK4 gene expression was detected in
thymocytes (Fig. 3 A). To investigate further the lack of
expression of MKK4 in the thymus, we examined MKK4
protein expression by Western blotting. High levels of
MKK4 protein were observed in the brain, but almost un-
detectable levels of MKK4 were found in the thymus (Fig.
3 B). We have also examined the expression of JNK pro-
tein in these tissues and found similar expression of JNK1
and JNK2 proteins in the brain and thymus. Since DP thy-
mocytes constitute the most abundant population (80–
85%) in the thymus, these results suggested that MKK7,
not MKK4, is the primary regulator of JNK in DP thy-
mocytes.
Generation of Dominant Negative JNK Transgenic Mice.
Activation of JNK in vivo (6–12 h; Fig. 1 B) appears to
Figure 2. TCR-mediated deletion of DP thymocytes in vivo and in
vitro. (A) Total thymocytes from untreated mice were incubated for 24 h
in the presence of medium alone (Control) or immobilized anti-CD3 (10
mg/ml) plus anti-CD28 (10 mg/ml) mAbs (In vitro anti-CD3/anti-CD28);
total thymocytes were isolated from mice injected with anti-CD3 mAb
(2C11, 50 mg/200 ml PBS) for 2 d (In vivo anti-CD3). The cells were
stained with anti-CD4 and anti-CD8 mAbs and analyzed by flow cytom-
etry. Profiles for CD4 and CD8 expression in gated live cells are pre-
sented. Numbers represent the percentage of each population (DP,
CD41, and CD81). (B) Total thymocytes were incubated for 24 h in the
presence of medium alone (Control) or Con A (2.5 mg/ml) (ConA). The
cells were then examined as described in A.
Figure 3. MKK4 and MKK7 expression in thymocytes. (A) MKK4
and MKK7 gene expression. Total RNA was isolated from the thymus or
brain from wild-type mice and analyzed by Northern blot as described in
Materials and Methods, using specific 32P-labeled cDNA probes for
MKK7, MKK4, and HPRT genes. (B) MKK4 and JNK protein expres-
sion. Whole extracts were obtained from the thymus and brain from
wild-type mice and analyzed by Western blot as described in Materials
and Methods using an anti-MKK4 specific mAb or anti-JNK polyclonal
antibody.1821 Rincón et al.
precede deletion of DP thymocytes (24–48 h) in response
to anti-CD3 mAb treatment (Fig. 2 A). To determine
whether JNK activation was a cause of DP thymocyte de-
letion we generated transgenic mice that overexpressed a
dominant negative form of JNK1 (dnJNK1; T 183 A and Y
185 F) (21) under the control of the distal lck promoter (22)
(Fig. 4 A). Three founder animals were obtained, each of
which expressed dnJNK1 mRNA in the thymus (Fig. 4 B).
In addition to the thymus, the dnJNK1 transgene was also
expressed in the spleen and purified T cells at levels sub-
stantially higher than the endogenous JNK1 gene (Fig. 4
C). Semi-quantitative analysis showed that the mRNA lev-
els for the dnJNK1 transgene in the thymus were at least
fivefold higher than the levels of endogenous JNK1
mRNA (Fig. 4 D).
No significant JNK activity was detected in unstimulated
thymocytes from either wild-type or dnJNK1 mice (Fig. 4
E). Stimulation with PMA and ionomycin activated JNK
in thymocytes from negative littermate control mice (Fig. 4
E). However, the activation of JNK was significantly com-
promised in dnJNK1 thymocytes (Fig. 4 E), indicating that
the overexpression of dnJNK1 inhibits endogenous JNK.
The AP-1 transcription factor is activated by the JNK
pathway at least in part by phosphorylation of the transacti-
vation domain of c-Jun (4, 5). Although substrates other
than AP-1 may be regulated by JNK in the DP thy-
mocytes, AP-1 transcriptional activity cannot be induced in
DP cells even in response to TCR-independent signals
(41). In contrast, AP-1 transcriptional activity is induced in
peripheral T cells in response to protein kinase C and cal-
Figure 4. Generation and
characterization of lck-dnJNK1
transgenic mice. (A) Schematic
representation of the dnJNK1
transgene. The dnJNK1 cDNA
in which Thr183 and Tyr185 were
replaced by Ala and Phe, respec-
tively, was subcloned down-
stream of the distal lck promoter
and upstream of the hGH poly-
adenylation signals and intron se-
quences. (B) Expression of the
dnJNK1 transgene. The presence
of the dnJNK1 mRNA was ana-
lyzed in total thymocytes from
positive mice from three inde-
pendent transgenic lines (Tg1;
lines 37, 44 and 45) or from
negative littermate control mice
(NLC) by reverse transcriptase-
PCR using specific primers for
the dnJNK1 transgene. As posi-
tive control, g-actin primers
were used. (C) Comparative ex-
pression of the endogenous
JNK1 gene and the dnJNK1
transgene. cDNA from spleen or
purified T cells from a dnJNK1
transgenic mouse (line 44) was
analyzed by PCR using specific
primers for endogenous mouse
JNK1, the dnJNK1 transgene, or
HPRT. (D) Semiquantitative
PCR analysis for the expression
of the endogenous JNK1 gene
and dnJNK1 transgene using dif-
ferent amounts of cDNA (0.5,
2.5, and 5 ml in the left, center,
and right lanes, respectively) pre-
pared from the thymus of a
dnJNK1 mouse. (E) JNK1 activ-
ity is reduced in dnJNK1 mice.
Total thymocytes (5 3 105) from
dnJNK1 (Tg1) or negative lit-
termate control mice were un-
stimulated or stimulated with
PMA (5 ng/ml) plus ionomycin (250 ng/ml) (P/I) for 30 min, harvested, and lysed. Whole extracts were assayed for JNK activity using the substrate
GST–c-Jun (26). (F) AP-1 transcriptional activity is inhibited in dnJNK1 transgenic mice. T cells (5 3 105 cells) were purified from AP-1–luciferase
reporter transgenic mice (NLC) or double AP1-luciferase 3 dnJNK1 transgenic mice (Tg1) and were incubated with medium alone (2) or with PMA (5
ng/ml) plus ionomycin (250 ng/ml) (P/I). After 24 h, the cells were harvested and luciferase activity was measured. The data shown are representative of
two independent experiments.1822 JNK Signaling Pathway in Thymic Development
cium signals (25). To further demonstrate the functionality
of the dominant negative JNK1 in the dnJNK1 mice, we
crossed these transgenic mice with AP-1–luciferase reporter
transgenic mice in which the expression of a luciferase re-
porter gene is driven by AP-1 DNA regulatory elements
(16, 25, 26, 41, 42). Since AP-1 activity cannot be induced
in DP thymocytes, we isolated peripheral CD41 T cells
from AP-1–luciferase transgenic mice or from AP-1–luci-
ferase 3 dnJNK1 double transgenic mice and stimulated
them with PMA and ionomycin. AP-1 transcriptional ac-
tivity was induced in T cells from negative littermates but
was significantly reduced in the dnJNK1 transgenic mice,
establishing that the dominant negative transgene could in-
deed antagonize signal transduction by JNK (Fig. 4 F).
T Cell Proliferative Response in dnJNK1 Mice. We exam-
ined the CD41 and CD81 T cell subsets in peripheral lym-
phoid organs. The frequency of CD41 and CD81 T cells in
lymph nodes (Fig. 5 A) and spleen (data not shown) was indis-
tinguishable between negative littermate control and dnJNK1
transgenic mice. The TCR expression levels were also normal
in T cells from dnJNK1 transgenic mice (data not shown).
We have demonstrated previously that TCR-mediated
signals in combination with costimulatory signals induce
AP-1 transcriptional activity and JNK in peripheral CD41
T cells (25, 26). To determine the role of JNK in T cell ac-
tivation we examined the proliferative response of total
spleen cells induced by Con A, anti-CD3 mAb, or PMA
plus ionomycin. A small reduction in proliferation was re-
producibly observed in the dnJNK1 mice (Fig. 5 B). How-
ever, the proliferative response of purified peripheral CD41
T cells in the presence of a limiting number of wild-type
APCs was significantly reduced (67%) in the dnJNK1 mice
(Fig. 5 C). The extent of inhibition of the proliferation of
dnJNK1 CD41 T cells decreased as the number of APCs
was increased. This dependence on APC number may ac-
count for the weak effect of the dnJNK1 transgene in the
cultures using total spleen cells where the ratio of APCs to
T cells is relatively high.
Figure 5. Proliferative T cell response in dnJNK1 mice. (A) Cell surface staining for CD4 and CD8 in total lymph node cells from dnJNK1 transgenic
(line 44) (Tg1) or negative littermate control (NLC) mice was analyzed by flow cytometry. The numbers represent the percentage of cells in each quad-
rant. (B) Spleen cells (2 3 105 cells/well) from dnJNK1 (Tg1) or negative littermates control (NLC) mice were stimulated with Con A (2.5 mg/ml),
anti-CD3 mAb (1 mg/ml), or PMA (5 ng/ml) plus ionomycin (250 ng/ml) (P/I) and proliferation was determined by [3H]thymidine incorporation. Re-
sults are representative of three independent experiments. (C) Purified CD41 T cells (5 3 104 cells/well) from dnJNK1 (Tg1) and negative littermate
control (NLC) mice were stimulated with Con A (2.5 mg/ml) in the presence of the indicated numbers of mitomycin C (50 mg/ml) treated splenocytes
from wild-type mice as the source of APC. Numbers (%) represent the percentage of proliferation of dnJNK1 CD41 T cells compared with the prolifer-
ation of CD41 T cells from NLC mice.
Figure 6. Normal positive selection in dnJNK1 transgenic mice. (A)
Cell surface staining for CD4 and CD8 in total thymocytes from dnJNK1
transgenic (line 44) (Tg1) or negative littermate control (NLC) mice was
analyzed by flow cytometry. The numbers represent the percentage of
cells in each quadrant. (B) Total thymocytes from Cyt c TCR transgenic
mice (NLC) or Cyt c TCR 3 dnJNK1 double transgenic mice (Tg1)
were analyzed for CD4 and CD8 expression in the total thymus (top) and
Vb3 expression in the DP or single CD41 gates (bottom). The numbers in-
dicate the percentage of DP CD41CD81 and SP CD41 cells in the total
thymus.1823 Rincón et al.
JNK Does Not Affect Positive Selection of Thymocytes. To
examine the effect of the overexpression of the dnJNK1
transgene on the development of T cells in the thymus, we
analyzed the distribution of thymic populations. The ratio
of DN, DP, and SP CD41 and CD81 thymocytes was not
significantly affected in the dnJNK1 transgenic mice (Fig. 6
A). The number of total thymocytes was slightly increased
(10–20%) in adult (.8 wk) dnJNK1 transgenic mice com-
pared with negative littermate control mice, although a
greater difference between dnJNK and wild-type thy-
mocyte numbers (twofold) was observed in very young
dnJNK1 transgenic mice (4–6 wk).
To test the effect of the dnJNK1 transgene expression on
positive selection, we crossed these mice with transgenic
mice expressing a TCR from a CD41 clone specific for
moth Cyt c (43). This TCR is strongly positively selected
in the H-2k MHC background, as shown by the pro-
nounced accumulation of the single CD41 TCR Vb31
cells, together with a reduction in the DP cells (Fig. 6 B).
No differences were observed in thymic populations and
the levels of specific TCR (Vb3) between transgene-posi-
tive and transgene-negative mice showing the accumula-
tion of SP CD41 TCR Vb31 cells in both cases. These re-
sults suggest that positive selection is unaffected by
dominant negative JNK1. Thus, the ERK pathway (8, 11),
but not the JNK pathway, appears to be required for posi-
tive selection.
JNK Signaling Pathway Contributes to the Deletion of DP
Thymocytes In Vivo. To examine negative selection in the
dnJNK1 transgenic mice, we first analyzed the deletion of
DP thymocytes induced by anti-CD3 mAb treatment in
vivo. As shown above, 2 d after injection with anti-CD3
Figure 7. Deletion of DP cells by anti-CD3 mAb in
vivo administration is impaired in dnJNK1 transgenic
mice. (A) dnJNK1 transgenic (Tg1) and negative litter-
mate control (NLC) mice (from line 44) were interperito-
neally injected with purified anti-CD3 mAb (50 mg/200
ml PBS). 2, 4, or 8 d after injection total thymocytes were
stained and CD4 and CD8 expression in the live popula-
tion was analyzed. The time at 0 d shows the thymocyte
distribution in uninjected mice. Numbers represent the
percentage of live cells in each gate, CD41CD81 (upper
gate) and single CD41 (lower gate). Data shown are from
one representative experiment out of three carried out. (B)
dnJNK1 transgenic (Tg1) and negative littermate control
(NLC) mice from line 45 were injected with anti-CD3
mAb (50 mg/200 ml PBS) and thymocytes were analyzed
2 d later as described in A. (C) Percentage of DP thy-
mocytes (top) and absolute number of DP thymocytes (bot-
tom) in the thymus from negative littermate control (NLC)
and dnJNK1 transgenic (Tg1) mice 2 d (left) or 8 d (right)
after anti-CD3 mAb in vivo administration. The mean and
standard deviations from four (day 2) and three (day 8) in-
dependent experiments are presented. (D) dnJNK1 trans-
genic (Tg1) and negative littermate control (NLC) mice
were injected with purified anti-CD3 mAb. The thymus
was isolated 2, 4, or 8 d after injection and from control
mice (0 d). Total thymocytes were analyzed by forward scatter (FSC) and side scatter (SSC) flow cytometry parameters. Numbers express the percentage
of cells in each gate, live cells (right gates) and dead cells (left gates). Data represent one experiment of three performed and represent an independent exper-
iment from the data presented in A.1824 JNK Signaling Pathway in Thymic Development
mAb in vivo, the DP population was almost completely
eliminated in negative littermate control mice (Fig. 7 A). In
contrast, a higher proportion (three- to fivefold) of DP cells
remained viable in dnJNK1 transgenic mice (line 44) (Fig.
7 A). The same results were obtained with transgenic mice
derived from a second transgenic line (line 45) (Fig. 7 B).
The fact that the inhibition mediated by this transgene is
incomplete is not surprising since similar partial inhibition
phenotypes were obtained with other dominant negative
transgene models (8, 9, 11). Moreover, it is possible that
the dnJNK1 transgene may not ablate signals mediated by
other members of the JNK family, for example JNK2.
Nevertheless, the percentage and absolute number of DP
thymocytes recovered after 2 d of anti-CD3 mAb injection
in dnJNK1 transgenic mice were consistently higher than
those in negative littermate control mice (Fig. 7 C). Thus,
inhibition of the JNK signaling pathway partially protected
DP thymocytes from deletion in vivo.
4 d after administration of anti-CD3 mAb, most of the
DP thymocytes were also deleted in dnJNK1 mice, al-
though the percentage of this population was still higher
than in negative littermates (Fig. 7 A). Interestingly, 8 d af-
ter injection of anti-CD3, the DP population was dramati-
cally reconstituted in the dnJNK1 transgenic mice (Fig. 7,
A and C). In contrast, this recovery was not observed in
negative littermate control mice (Fig. 7, A and C). More-
over, the number of total thymocytes (data not shown) and
the number of DP thymocytes recovered after 8 d of injec-
tion (Fig. 7 C) were substantially increased (7–14-fold) in
the dnJNK1 transgenic mice. Therefore, the dnJNK1
transgenic mice showed delayed elimination and acceler-
ated reconstitution of the DP population in response to
anti-CD3 mAb administration in vivo, likely due to an in-
creased resistance to cell death.
To demonstrate that the reduced deletion of the DP
population was associated with an inhibition of apoptosis in
the thymus, we examined the morphology of the thy-
mocytes by FACSÒ analysis using side scatter and forward
scatter as parameters for the complexity (e.g., granularity)
and the size of cells, respectively. Thymocytes were iso-
lated and analyzed at different time points after anti-CD3
mAb administration. It has been shown previously (44) that
apoptotic cells present reduced forward scatter (reduced
size) and higher side scatter (higher complexity) compared
with live cells (which exhibit higher forward scatter and
lower side scatter). 2 d after anti-CD3 mAb injection, the
percentage of the apoptotic population was reduced (three-
to fivefold), while the percentage of the live population
was increased in the dnJNK1 transgenic mice compared
with wild-type mice (Fig. 7 D). Although smaller differ-
ences were observed at day 4, after 8 d a significantly
higher proportion of apoptotic cells remained in the nega-
tive littermate control mice. In contrast, only a few apop-
totic cells were observed in the dnJNK1 transgenic mice
and the live thymocyte population had almost fully recov-
ered (Fig. 7 D). Taken together, these data indicate that
JNK is required for the complete deletion of DP thy-
mocytes by apoptosis in vivo.
To further confirm that TCR-mediated negative selec-
tion in the thymus is regulated by JNK, we examined the
deletion of autoreactive thymocytes induced by specific
self-antigens. The dnJNK1 transgenic mice were crossed
with Cyt c–reactive TCR transgenic mice. As described
above, the expression of the dnJNK1 transgene did not af-
fect positive selection of Cyt c-bearing thymocytes (Fig. 6
B). A specific Cyt c peptide was administrated to the Cyt c
TCR transgenic mice and the Cyt c–specific TCR 3
dnJNK1 double transgenic mice. After 20 h, the thymic
populations were examined. The percentage of apoptotic
thymocytes was increased and the live population was re-
duced in the Cyt c TCR transgenic mice upon peptide ad-
ministration (Fig. 8 A). In contrast, no significant increase
of thymocyte cell death was observed in the Cyt c TCR 3
dnJNK1 double transgenic mice in response to the peptide
Figure 8. Antigen-specific induced apoptosis in thymus is impaired in dnJNK1 transgenic mice. (A) Cyt c TCR transgenic mice (NLC) or Cyt c TCR 3
dnJNK1 double transgenic mice (Tg1) were injected with PBS or a synthetic moth Cyt c peptide (250 mM/200 ml/mouse) for 24 h. Thymocytes were
then isolated, stained, and analyzed by flow cytometry for side scatter (SSC) and forward scatter (FSC) flow cytometry. Numbers express the percentage
of cells in each gate, live cells (right gates) and dead cells (left gates). (B) CD4 and CD8 expression in live cells from Cyt c TCR transgenic mice (NLC) or
Cyt c TCR 3 dnJNK1 double transgenic mice (Tg1) injected with PBS or a synthetic moth Cyt c peptide for 24 h. Numbers represent the percentage
of cells in each gate (DP, CD41, and DN cells). (C) Absolute number of DP, CD41, and DN cells in Cyt c TCR transgenic mice (NLC) or Cyt c TCR 3
dnJNK1 double transgenic mice (Tg1) 24 h after injection with a synthetic moth Cyt c peptide. A total of 40–60 3 106 cells was found in thymuses from
both Cyt c TCR transgenic mice and Cyt c TCR 3 dnJNK1 double transgenic mice before peptide injection. The results are representative of two
independent experiments.1825 Rincón et al.
(Fig. 8 A). The percentage of DP and mature CD41 thy-
mocytes recovered upon peptide injection was only slightly
increased in the dnJNK1 3 Cyt c double transgenic mice
(Fig. 8 B). However, the absolute numbers of DP and
CD41 thymocytes were higher (two- to threefold) in the
Cyt c TCR 3 dnJNK1 double transgenic mice than in the
Cyt c TCR transgenic mice (Fig. 8 C). These results indi-
cated that deletion of autoreactive thymocytes by specific
antigens is impaired in the dnJNK1 mice.
Regulation of In Vitro DP Thymocyte Deletion by JNK.
We have shown that JNK activity was not significantly in-
duced in DP thymocytes in response to a combination of
anti-CD3 and anti-CD28 mAbs (Fig. 1 A). In correlation
with these results, we did not observe significant differences
in the percentage (Fig. 9 A) or absolute number (data not
shown) of DP thymocytes recovered after 16 h of treat-
ment with anti-CD3 and anti-CD28 mAbs in vitro be-
tween the dnJNK1 transgenic and wild-type mice.
We also examined thymic deletion induced by Con A
treatment in vitro, which significantly activated JNK in DP
thymocytes (Fig. 1 C). Con A–mediated signals rapidly in-
duced pronounced thymocyte death and loss of the abso-
lute number of DP cells (data not shown). However, thy-
mocytes from dnJNK1 mice were more resistant to Con
A–induced cell death, as shown by increased viable total
thymocytes (Fig. 9 B) and the percentage of live DP cells
(Fig. 9 A). Together, these data indicate that JNK is also
important to induce cell death in DP thymocytes by signals
mediated by the TCR and costimulatory molecules in
vitro.
Discussion
The balance of survival signals (positive selection) and
death signals (negative selection) is critical for the develop-
ment of T cells with an appropriate repertoire in the thy-
mus. A predominance of survival signals could lead to the
presence of autoreactive cells in the periphery that have es-
caped negative selection in the thymus. Similarly, excessive
cell death may cause immunodeficiencies due to underrep-
resentation of the complete repertoire. Thus, it is important
to dissect the molecular mechanisms utilized by the TCR
as well as other molecules that lead to a survival or death
signal in developing thymocytes. Moreover, it is critical to
determine whether these mechanisms are common to the
activation signals in mature T cells in the periphery.
The MAP kinase family is widely implicated in the con-
trol of survival and death in several cellular systems (4, 5).
The ERK-MAP kinase pathway is primarily associated
with cell survival and proliferation. In contrast, both the
p38 and the JNK pathways have often been related to in-
duction of apoptosis or cell death.
Inhibition of the ERK pathway by retroviral-mediated
overexpression of a dominant negative MEK (an upstream
activator of ERK) in fetal thymic organ culture causes im-
paired differentiation of DN into DP thymocytes (7). In
correlation, inhibition of the ERK pathway by the
PD98059 drug also causes a partial reduction of the expan-
sion and differentiation of DN into DP cells (13). In con-
trast, overexpression of dnMEK1 in transgenic mouse
models did not significantly affect this stage of thymic de-
velopment (8, 11). The role of p38 MAP kinase in thymic
development has not yet been addressed, although the high
level of constitutive p38 activity detected in DN and DP
thymocytes (14) suggests that p38 may also contribute to
the differentiation of DN to DP thymocytes. Here, we
show that inhibition of the JNK pathway in dnJNK1 trans-
genic mice does not affect the development of DP from
DN thymocytes. However, the distal lck promoter (22)
used to generate these mice does not drive high levels of
expression in DN thymocytes. Thus, based on our studies,
we cannot conclude that the JNK pathway is not involved
in the control of DN differentiation.
The Ras/Raf–ERK signaling pathway is required for
positive selection of DP thymocytes, as shown by the ef-
fects of overexpression of dominant interfering forms of
Ras, Raf, or MEK (8, 9, 11, 12). In contrast, no effect on
negative selection of this pathway has been observed in
these studies, suggesting that the ERK pathway is not re-
quired for negative selection of DP thymocytes. Here, we
Figure 9. TCR-mediated de-
letion of DP thymocytes in vitro
from dnJNK1 mice. (A) Total
thymocytes from dnJNK1 trans-
genic (Tg1) and negative litter-
mate control (NLC) mice were
incubated in the presence of me-
dium (2), or immobilized anti-
CD3 (10 mg/ml) plus anti-CD28
(10  mg/ml) mAbs (anti-CD3/
anti-CD28) or Con A (2.5 mg/
ml). After 24 h, the cells were
harvested, stained with anti-CD4
and anti-CD8 mAbs, and ana-
lyzed by FACSÒ. The profiles
represent CD4 and CD8 expres-
sion in live cells. Numbers represent the percentage in each gated population. (B) Total thymocytes from dnJNK1 transgenic (Tg1) and negative litter-
mate control (NLC) mice were incubated in the presence of medium (2) or Con A (2.5 mg/ml). Cell viability was analyzed by trypan blue staining at the
indicated times. The results presented are representative of three independent experiments.1826 JNK Signaling Pathway in Thymic Development
show that inhibition of the JNK pathway does not affect
positive selection of DP thymocytes, but instead results in
defective deletion of DP thymocytes in response to nega-
tive selection signals. These results correlate with previous
studies in other cellular systems that have demonstrated an
association of the ERK and JNK pathways with survival
and death signals, respectively (4, 5, 45).
In contrast to the high p38 activity that we (46) and oth-
ers (14) have detected in unstimulated thymocytes, only
very low JNK activity was detected in thymocytes before
activation. Here, for the first time, we show that the JNK
pathway is activated in vivo in DP thymocytes in response
to TCR-mediated signals, probably in combination with
additional signals provided by the thymic environment (see
below). The activation of JNK in DP thymocytes precedes
the induction of apoptosis and deletion of these cells, sug-
gesting that the activation of JNK could be required for the
initiation of the apoptotic cascade. The phenotype of the
dnJNK1 transgenic mice support this model. First, we have
demonstrated that DP thymocytes from the dnJNK1 trans-
genic mice are more resistant to deletion induced by anti-
CD3 mAb in vivo. Injection with anti-CD3 has been
widely used to study negative selection in non-TCR trans-
genic mouse models (36–40). The strong signal induced by
the ligation of the TCR with an anti-CD3 mAb may
mimic the signals that are clonally induced by high signal
intensity TCR ligands, such as negative selecting peptides
(47–50). In addition, similar results were obtained when a
specific peptide was used to induce antigen-dependent de-
letion of DP thymocytes. Therefore, we have shown that
thymocytes from Cyt c TCR transgenic mice are more re-
sistant to in vivo cell death in response to the more relevant
signal delivered by a specific Cyt c peptide when the JNK
pathway is impaired. Moreover, deletion of DP thymocytes
upon injection of Staphylococcus enterotoxin B superantigen
in vivo was also reduced in the dnJNK1 transgenic mice,
although no significant differences were observed in the
deletion of Vb5 and Vb11 mature thymocytes by endoge-
nous viral superantigens (data not shown). Thymocytes
from dnJNK1 transgenic mice are also more resistant to cell
death induced by Con A in vitro. The four approaches to-
gether provide strong support for the requirement of JNK
in the deletion of DP thymocytes. Further work will be re-
quired to determine the role of JNK in deletion mediated
by endogenous superantigens.
The reduced deletion of dnJNK1 DP thymocytes ap-
pears to be caused by increased resistance to apoptosis, as
shown by the reduction of the number of apoptotic cells
and the increase of live thymocytes after 2 d of anti-CD3
mAb treatment in vivo. Furthermore, the resistance of DP
thymocytes from the dnJNK1 transgenic mice to cell death
is consistent with the accelerated reconstitution of the DP
population in these mice after the deletion caused by anti-
CD3 mAb administration. After 8 d of anti-CD3 mAb in-
jection, almost no thymocytes were found in the wild-type
thymus, whereas the number of thymocytes from dnJNK1
mice was substantially increased. Analysis of thymic popu-
lations at this time demonstrated that the DP population is
recovered in dnJNK1 mice, whereas no DP thymocytes
were detected in wild-type mice. Together, these data in-
dicate that inhibition of the JNK pathway renders DP thy-
mocytes more resistant to death signal and they can expand
and repopulate the thymus more rapidly.
Activation of the protein kinase C or Ras pathways by
PMA is not sufficient to induce JNK activity in Jurkat T
cells and thymocytes; an additional calcium signal is also re-
quired to activate JNK (6), indicating the importance of the
calcium pathway in the regulation of JNK. A role for cal-
cium signals in thymocyte negative selection has been sug-
gested by a number of studies (50–53). Defective negative
selection associated with reduced calcium flux in response
to TCR stimulation has been found in mice deficient for
the protooncogene Vav (54) which functions as a guanine
nucleotide exchange factor for the Rho/Rac/cdc42 family
of GTPases (55–57). Interestingly, Vav can transduce a sig-
nal that leads to the activation of the JNK pathway in a
Rac-1–dependent manner (58, 59). Thus, the calcium re-
quirement for negative selection and for JNK activation
correlates with the requirement of JNK activation for neg-
ative selection that we propose in this study and has been
previously suggested by others (54).
The ERK pathway is required not only for positive se-
lection, but it is also involved in T cell lineage commit-
ment. It has been shown that the overexpression of a
dominant gain-of-function mutant of ERK2 favored dif-
ferentiation of DP thymocytes to the CD41 lineage (13)
and that pharmacological inhibition of this pathway favors
differentiation to the CD81 lineage. In contrast to the
study by Sharp et al. (13), the inhibition of the ERK path-
way in mice overexpressing a dominant negative Mek-1
did not affect CD81 T cell development (8, 11). We did
not observe significant differences in CD41 and CD81 lin-
eages in the dnJNK1 transgenic mice, but we cannot elim-
inate the possibility that JNK may also be involved in lin-
eage commitment.
The JNK-MAP kinase group is formed by three genes:
JNK1, JNK2, and JNK3. Each of these genes expresses sev-
eral JNK isoforms that are generated by alternative splicing
(15). JNK family members are phosphorylated and acti-
vated by members of the MAPK kinase family. Sek1/
MKK4 was the first activator to be identified (17–19). We
and others have shown that JNK activation is not com-
pletely abrogated in Sek1/MKK4 deficient cells and that
the extent of inhibition depends on the stimulus used (60,
61). More recently, a new activator of JNK has been iden-
tified (20). This activator, MKK7, may also contribute to
JNK regulation in thymocytes. The contribution of these
two activators, MKK4 and MKK7, in the regulation of
JNK activity in vivo remains to be determined.
It has been reported that DP thymocytes from Rag22/2
chimeric Sek1/MKK4 deficient mice are more susceptible
to cell death induced in vitro by anti-Fas or anti-CD3
mAbs, but not by anti-CD3/anti-CD28 mAbs (60). The
deletion of DP cells in vivo was not examined in Sek1/
MKK4 deficient mice (60). A role for the JNK signaling
pathway in the inhibition of apoptosis during T cell devel-1827 Rincón et al.
opment was suggested in this study. However, more re-
cently, similar studies by Swat et al. (62) have shown that
thymic development is normal in Rag22/2 chimeric
Sek1/MKK4 deficient mice, but the mice develop lymph-
adenopathy. Thus, these results indicate that MKK4 is not
relevant for development of T cells in the thymus. In cor-
relation, we have found that MKK4 is expressed only at
very low levels in thymocytes. Thus, it is surprising that de-
letion of a gene (MKK4) which is not expressed (neither as
RNA nor as protein) in the thymus could result in a sub-
stantial phenotype, as observed by Nishina et al. (60).
However, in contrast to MKK4, we have shown that
MKK7 is highly expressed in the thymus, suggesting that
MKK7, and not MKK4, is the major regulator on the JNK
pathway in thymocytes. Therefore, it is likely that MKK7
mediates the activation of JNK in DP thymocytes in re-
sponse to anti-CD3 mAb treatment in vivo. Moreover,
studies by Swat et al. (62) indicate that MKK4 is required
for maintaining peripheral lymphoid homeostasis. Our data
indicate that the activation of JNK probably by MKK7 is
required for complete elimination of DP cells in vivo in the
thymus. Together, these results suggest a differential regu-
lation of JNK in immature thymocytes and mature T cells.
The specific role of MKK7 in T cell development and T
cell activation remains to be addressed.
It is well accepted that the negative selection of autore-
active cells in the thymus requires costimulatory signals in
addition to the TCR-mediated signal. However, the na-
ture of the costimulatory signals remains unclear (31–33).
CD28 is able to provide the signal requirement for negative
selection of immature heat stable antigen, HSAlow, CD41
thymocytes (34). In contrast, the CD28 costimulatory sig-
nal does not appear to be sufficient, even in conjunction
with TCR ligation, to induce deletion of DP thymocytes.
Thus, in vitro stimulation of thymocytes with immobilized
anti-CD3 mAb in combination with anti-CD28 mAb
caused downmodulation of CD4 and CD8 molecules on
the surface of DP thymocytes. However, this stimulation
does not induce complete deletion of the DP population,
although the CD4lowCD8low subpopulation has been char-
acterized as apoptotic cells (35). Moreover, the specific role
of B7.1 and B7.2 molecules in the deletion of DP thy-
mocytes remains controversial (33, 63, 64). In contrast to
these in vitro studies, the presence of anti-CD3 mAb or
other TCR ligands (e.g., superantigens, specific antigens)
alone induces significant deletion of DP thymocytes in
vivo. Together, this evidence suggests that thymic environ-
mental signals other than CD28 may play an important role
in negative selection of autoreactive T cells. Thus, CD30
deficient mice contain elevated numbers of thymocytes,
and negative selection, but not positive selection, is defec-
tive in these mice, suggesting that CD30 is an important
coreceptor in deletion of autoreactive T cells (65). CD40
ligand has also been reported to play a role in negative se-
lection (66).
In correlation with the requirements for negative selec-
tion, we show here that JNK activity is not upregulated in
DP thymocytes stimulated with immobilized anti-CD3 and
anti-CD28 mAbs in vitro (Fig. 1 A). In contrast, Con A
stimulation induced JNK activity in DP thymocytes in
vitro. Since Con A is a lectin that can bind molecules other
than the TCR, it is possible that these other accessory mol-
ecules provide the costimulatory signals required for the ac-
tivation of JNK by TCR ligation. In addition, the adminis-
tration of anti-CD3 mAb in vivo also induced JNK
activation in DP thymocytes, suggesting a requirement of
additional thymic environmental components for the acti-
vation of JNK through the TCR. The studies performed in
the dnJNK1 mice confirm these results. Deletion of DP
thymocytes by either Con A treatment in vitro or anti-
CD3 mAb administration in vivo is impaired in the
dnJNK1 mice. In contrast, cell death induced by anti-
CD3/anti-CD28 mAb treatment in vitro was not affected
in these mice.
In our in vivo models, we cannot distinguish whether
the inhibition of JNK directly affects TCR-mediated nega-
tive signals or whether it affects any other signals delivered
by the thymic environment (e.g., cytokines, accessory mol-
ecules). Nevertheless, it has not yet been established that
TCR signal delivered during negative selection directly
causes apoptosis. Therefore, it is also possible that TCR-
mediated signals only sensitize DP thymocytes to apoptotic
stimuli provided by other environmental factors, such as
members of the TNF receptor (TNFR) families (including
Fas, CD30, CD40, and TNFR), as has been suggested pre-
viously (67).
We have shown for the first time that JNK is activated in
DP thymocytes in vivo, and this activation is likely medi-
ated by MKK7, rather than MKK4. Deletion of DP thy-
mocytes in vivo by apoptosis is impaired in dnJNK1 trans-
genic mice, indicating that signaling via JNK contributes to
negative selection in the thymus. We propose that a down-
stream target of JNK contributes to the apoptotic response
in thymocytes during negative selection, as described for
the apoptotic responses in other cell types (5, 16, 45, 68,
69). Thus, during thymocyte development the positive se-
lection of CD41 T cells is mediated through the ERK
pathway, as shown by Perlmutter and colleagues (8, 11),
while JNK contributes to negative selection. Together,
these results support a qualitative rather than quantitative
model to explain how recognition of each peptide-MHC
complex results in a different final outcome, positive versus
negative selecting signals, via the ERK and JNK pathways,
respectively.
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